Publicacións en colaboración con investigadores/as de Hospital Universitario La Fe (16)

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

2023

  1. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2018

  1. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537

  2. SEOM clinical guideline in nasopharynx cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 84-88

2017

  1. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

  2. Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

    Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137

2015

  1. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

    Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750

2012

  1. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

    Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665

  2. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

    Breast Cancer Research and Treatment, Vol. 132, Núm. 1, pp. 307-315

  3. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors

    Journal of Neuro-Oncology, Vol. 109, Núm. 1, pp. 137-142

  4. SEOM guideline for the treatment of malignant glioma

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550

2010

  1. Extended-schedule dose-dense temozolomide in refractory gliomas

    Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422

2009

  1. Spanish society of medical oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 7, pp. 446-454